Showing results (211-220 of 259) with videos related to
Sort By:
Pageof 26
Future Oncology (London, England)|December 18, 2025
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trialMyung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, et al.Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.The Oncologist|May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.Cancers|October 28, 2023
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)Yvonne L E Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, et al.British Journal of Cancer|March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.Cancer Discovery|October 20, 2022
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTONRyan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung CancerJames Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.EMBO Molecular Medicine|October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerMi Ran Yun, Hun Mi Choi, You Won Lee, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJonathan D Spicer, Tina Cascone, Murry W Wynes, et al.Pageof 26